New Concepts in the Management of Medullary Thyroid Cancer - Management of Medullary Thyroid Cancer

This live webinar series is an educational program that addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with medullary thyroid cancer (MTC).

Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma

Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.

Archived Monthly Oncology Tumor Boards: Management of Thyroid Carcinomas
Differentiated thyroid cancers have an excellent prognosis with appropriate treatment, and education in optimal management will help guide treatment decisions. For cases of thyroid cancer that require more aggressive treatment, knowledge of the most current treatment approaches can help clinicians give their patients a chance at the best possible outcome.
Monthly Oncology Tumor Boards: Management of Thyroid Carcinomas
Differentiated thyroid cancers have an excellent prognosis with appropriate treatment, and education in optimal management will help guide treatment decisions. For cases of thyroid cancer that require more aggressive treatment, knowledge of the most current treatment approaches can help clinicians give their patients a chance at the best possible outcome.
Recorded Presentation from the NCCN Pharmacy Updates: Updates on Targeted Therapy for the Treatment of Thyroid Carcinoma
Pharmacists should be aware of the new data and recommendations for targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
NCCN Pharmacy Updates: Updates on Targeted Therapy for the Treatment of Thyroid Carcinoma
Pharmacists should be aware of the new data and recommendations for targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options
Novel systemic therapy treatment options for patients with advanced thyroid carcinoma continue to be evaluated, including for anaplastic disease, which is almost uniformly lethal. Because some patients with medullary thyroid carcinoma may have indolent and asymptomatic disease, potentially toxic therapy may not be appropriate.
NCCN Guidelines® Insights - Thyroid Carcinoma, Version 2.2018

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas.

NCCN Guidelines® Insights - Thyroid Carcinoma, Version 2.2014

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine.

Recorded Presentation - NCCN Medullary Thyroid Cancer Webinar Series: Management of MEN2

This recorded webinar series is an educational program that addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with medullary thyroid cancer (MTC).

Pages

Subscribe to RSS - Thyroid Cancer